Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abeona Therapeutics
(NQ:
ABEO
)
5.515
+0.395 (+7.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abeona Therapeutics
< Previous
1
2
3
4
5
Next >
Calix Reports Mixed Results, Joins Cadence Design Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
April 23, 2024
Via
Benzinga
Abeona Therapeutics Provides Regulatory Update on Pz-cel
April 22, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 19, 2024
Via
Benzinga
Recap: Abeona Therapeutics Q3 Earnings
November 13, 2023
Via
Benzinga
ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023
March 19, 2024
ABEO stock results show that Abeona Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
March 18, 2024
- FDA completed Pre-License Inspection of Abeona’s Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study -
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
February 08, 2024
The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 07, 2024
Via
Benzinga
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
February 01, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces $50 Million Credit Facility
January 08, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 15, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
November 27, 2023
Via
Benzinga
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
November 27, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
November 13, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
The 7 Most Undervalued Penny Stocks to Buy in October 2023
October 06, 2023
Undervalued penny stocks offer tremendous return for investors with an appetite for risk but these shares are relatively safe as well.
Via
InvestorPlace
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
September 26, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
3 Biotech Blockbusters to Turn $5,000 Into $50,000
September 12, 2023
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time.
Via
InvestorPlace
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
September 12, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
September 07, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
August 30, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 02, 2023
Via
Benzinga
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
July 28, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Joins Rare Disease Company Coalition
July 19, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 07, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 03, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.